Live Breaking News & Updates on Superluminal Medicine

Stay updated with breaking news from Superluminal medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Twice Rejected Diabetes Drug/Device Product Gets New Chance at Startup i2O

Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2O Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds. ....

New Jersey , United States , San Diego , Harvard University , Samir Mitragotri , Andreesen Horowitz , Redmile Group , Rd Fund , Bain Capital Life Sciences , Intarcia Therapeutics , Sanofi Ventures , Epigenic Therapeutics , Qiming Venture Partners , Morningside Venture Capital , Superluminal Medicine , San Francisco Based Cellares , Koch Disruptive , Rapport Therapeutics , Asset Management , Genesis Therapeutics , Medcity News , Bain Capital Life , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News ,